Cargando…

Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy

Idiopathic pulmonary fibrosis (IPF) is a fatal progressive disease with a median survival of 2–5 years. Nintedanib is a small tyrosine kinase inhibitor that reduces IPF progression, significantly slowing the annual decline in Forced Vital Capacity (FVC). Very little data is available on the molecula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Landi, Claudia, Bergantini, Laura, Cameli, Paolo, d’Alessandro, Miriana, Carleo, Alfonso, Shaba, Enxhi, Rottoli, Paola, Bini, Luca, Bargagli, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287088/ https://www.ncbi.nlm.nih.gov/pubmed/32523095 http://dx.doi.org/10.1038/s41598-020-66296-z

Ejemplares similares

BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures
por: Vantaggiato, Lorenza, et al.
Publicado: (2023)

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
por: Cameli, Paolo, et al.
Publicado: (2020)

Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment
por: Vantaggiato, Lorenza, et al.
Publicado: (2022)

Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis
por: Bargagli, Elena, et al.
Publicado: (2020)

Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways
por: Shaba, Enxhi, et al.
Publicado: (2021)

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study
por: Cameli, Paolo, et al.
Publicado: (2022)

Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a New Protocol for Investigating the Mechanisms of Idiopathic Pulmonary Fibrosis
por: Bergantini, Laura, et al.
Publicado: (2022)

The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis
por: Refini, Rosa Metella, et al.
Publicado: (2020)

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena
por: Vietri, Lucia, et al.
Publicado: (2020)

High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?
por: Cameli, Paolo, et al.
Publicado: (2021)

Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
por: Bergantini, Laura, et al.
Publicado: (2021)

Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis (CSIPF): A New Phenotype or a Fortuitous Overlap? Scoping Review and Case Series
por: Bergantini, Laura, et al.
Publicado: (2022)

Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review
por: Bergantini, Laura, et al.
Publicado: (2022)

Prevalence of myositis specific and associated antibodies in a cohort of patients affected by idiopathic NSIP and no hint of inflammatory myopathies
por: Conticini, Edoardo, et al.
Publicado: (2023)

Neutrophil Extracellular Traps in ANCA-Associated Vasculitis and Interstitial Lung Disease: A Scoping Review
por: d’Alessandro, Miriana, et al.
Publicado: (2022)

Alteration of Serum Proteome in Levo-Thyroxine-Euthyroid Thyroidectomized Patients
por: Landi, Claudia, et al.
Publicado: (2022)

Extracellular Vesicles in Pulmonary Fibrosis Models and Biological Fluids of Interstitial Lung Disease Patients: A Scoping Review
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

KL-6 in ANCA-Associated Vasculitis Patients with and without ILD: A Machine Learning Approach
por: Conticini, Edoardo, et al.
Publicado: (2022)

Alveolar Nitric Oxide as a Biomarker of COVID-19 Lung Sequelae: A Pivotal Study
por: Cameli, Paolo, et al.
Publicado: (2021)

Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis
por: Bergantini, Laura, et al.
Publicado: (2022)

Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Neurodegenerative Disorder Risk in Krabbe Disease Carriers
por: Vantaggiato, Lorenza, et al.
Publicado: (2022)

Serum Amyloid A in lung transplantation
por: Vietri, Lucia, et al.
Publicado: (2020)

Proteome analysis of bronchoalveolar lavage in pulmonary langerhans cell histiocytosis
por: Landi, Claudia, et al.
Publicado: (2011)

Krebs von den Lungen-6 (KL-6) in cerebrospinal fluid from neurosarcoidosis patients
por: Bocci, Silvia, et al.
Publicado: (2023)

NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19
por: Bergantini, Laura, et al.
Publicado: (2021)

Proteomics Reveals How the Tardigrade Damage Suppressor Protein Teaches Transfected Human Cells to Survive UV-C Stress
por: Shaba, Enxhi, et al.
Publicado: (2023)

A Novel Ex Vivo Approach Based on Proteomics and Biomarkers to Evaluate the Effects of Chrysene, MEHP, and PBDE-47 on Loggerhead Sea Turtles (Caretta caretta)
por: Bianchi, Laura, et al.
Publicado: (2022)

Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6
por: Bergantini, Laura, et al.
Publicado: (2019)

Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases
por: Bergantini, Laura, et al.
Publicado: (2020)

Adaptive immune system in pulmonary sarcoidosis—Comparison of peripheral and alveolar biomarkers
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Immunological Pathways in Sarcoidosis and Autoimmune Rheumatic Disorders—Similarities and Differences in an Italian Prospective Real-Life Preliminary Study
por: d’Alessandro, Miriana, et al.
Publicado: (2023)

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
por: Glaspole, Ian, et al.
Publicado: (2021)

Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review
por: Cameli, Paolo, et al.
Publicado: (2020)

Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II
por: d’Alessandro, Miriana, et al.
Publicado: (2022)

Extracellular Vesicle Surface Signatures in IPF Patients: A Multiplex Bead-Based Flow Cytometry Approach
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

PD1, CTLA4 and TIGIT Expression on T and NK Cells in Granulomatous Diseases: Sarcoidosis and ANCA-Associated Vasculitis
por: d’Alessandro, Miriana, et al.
Publicado: (2022)

Imbalance of Lymphocyte Subsets and CD45RA-Expressing Cells in Intrathoracic Lymph Nodes, Alveolar Compartment and Bloodstream of Pulmonary Sarcoidosis Patients
por: d’Alessandro, Miriana, et al.
Publicado: (2023)

First Attempt to Couple Proteomics with the AhR Reporter Gene Bioassay in Soil Pollution Monitoring and Assessment
por: Landi, Claudia, et al.
Publicado: (2021)

Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone
por: Shaba, Enxhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_54to3q8bcufgvj4v0ojtt719kq